UAB is only one of four institutions nationwide to be named a prestigious "Specialized Program of Research Excellence" (SPORE). Clinicians work in close collaboration with experienced laboratory researchers to produce novel treatments for malignant brain tumors.

Clinical Trials

  • "A Randomized, Double Blind, Controlled Phase II Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients with Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation" Principal Investigator: James M. Markert, MD
  • "A Phase I/II Clinical Trial to Evaluate Dose Limiting Toxicity and Efficacy of Intralesional Administration of REOLYSIN for the Treatment of Patients with Histologically Confirmed Recurrent Malignant Gliomas" Principal Investigator: James M. Markert, MD
  • "Medigene CT-2001″ A Staged Phase I Study of the Treatment of Malignant Glioma with G207, a Genetically Engineered HSV-1, Followed by Radiation Therapy" Principal Investigator: James M. Markert, MD

james markert 2009 11-300x214Personnel

James M. Markert, MD, MPH

G. Yancey Gillespie, PhD

Corinne Griguer, PhD


For a list of publications by faculty member, please visit each physician's biography page.